Compare NUTX & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | XBIT |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 70.1M |
| IPO Year | 2009 | 2015 |
| Metric | NUTX | XBIT |
|---|---|---|
| Price | $209.38 | $2.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $252.50 | N/A |
| AVG Volume (30 Days) | ★ 117.6K | 43.1K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.93 | N/A |
| EPS | ★ 15.87 | N/A |
| Revenue | ★ $875,257,000.00 | N/A |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | $13.50 | ★ N/A |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $83.99 | $2.09 |
| 52 Week High | $224.28 | $3.44 |
| Indicator | NUTX | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 42.52 |
| Support Level | $142.71 | N/A |
| Resistance Level | N/A | $2.46 |
| Average True Range (ATR) | 10.19 | 0.05 |
| MACD | 1.29 | -0.00 |
| Stochastic Oscillator | 72.61 | 23.53 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.